Sarcoma (Jan 2024)

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum

  • Victor Rechl,
  • Andreas Ranft,
  • Vivek Bhadri,
  • Benedicte Brichard,
  • Stephane Collaud,
  • Sona Cyprova,
  • Hans Eich,
  • Torben Ek,
  • Hans Gelderblom,
  • Jendrik Hardes,
  • Lianne M. Haveman,
  • Wolfgang Hartmann,
  • Peter Hauser,
  • Philip Heesen,
  • Heribert Jürgens,
  • Jukka Kanerva,
  • Thomas Kühne,
  • Anna Raciborska,
  • Jelena Rascon,
  • Arne Streitbürger,
  • Yasmin Uhlenbruch,
  • Beate Timmermann,
  • Josephine Kersting,
  • Minh Thanh Pham,
  • Uta Dirksen

DOI
https://doi.org/10.1155/2024/4751914
Journal volume & issue
Vol. 2024

Abstract

Read online

Background. Ewing sarcoma (EwS) is a rare and highly malignant bone tumor primarily affecting children, adolescents, and young adults. The pelvis, trunk, and lower extremities are the most common sites, while EwS of the sacrum as a primary site is very rare, and only few studies focusing on this location are published. Due to the anatomical condition, local treatment is challenging in sacral malignancies. We analyzed factors that might influence the outcome of patients suffering from sacral EwS. Methods. We retrospectively analyzed data of the GPOH EURO-E.W.I.N.G 99 trial and the EWING 2008 trial, with a cohort of 124 patients with localized or metastatic sacral EwS. The study endpoints were overall survival (OS) and event-free survival (EFS). OS and EFS were calculated using the Kaplan–Meier method, and univariate comparisons were estimated using the log-rank test. Hazard ratios (HRs) with respective 95% confidence intervals (CIs) were estimated in a multivariable Cox regression model. Results. The presence of metastases (3y-EFS: 0.33 vs. 0.68; P<0.001; HR = 3.4, 95% CI 1.7 to 6.6; 3y-OS: 0.48 vs. 0.85; P<0.001; HR = 4.23, 95% CI 1.8 to 9.7), large tumor volume (≥200 ml) (3y-EFS: 0.36 vs. 0.69; P=0.02; HR = 2.1, 95% CI 1.1 to 4.0; 3y-OS: 0.42 vs. 0.73; P=0.04; HR = 2.1, 95% CI 1.03 to 4.5), and age ≥18 years (3y-EFS: 0.41 vs. 0.60; P=0.02; HR = 2.6, 95% CI 1.3 to 5.2; 3y-OS: 0.294 vs. 0.59; P=0.01; HR = 2.92, 95% CI 1.29 to 6.6) were revealed as adverse prognostic factors. Conclusion. Young age seems to positively influence patients` survival, especially in patients with primary metastatic disease. In this context, our results support other studies, stating that older age has a negative impact on survival. Tumor volume, metastases, and the type of local therapy modality have an impact on the outcome of sacral EwS. Level of evidence: Level 2. This trial is registered with NCT00020566 and NCT00987636.